An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Conditions
Oligometastatic Prostate Cancer (OMPC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Highlands Oncology Group, Fayetteville, Arkansas, United States
Contact: Principal Investigator (Joseph Thaddeus Beck)VA Greater LA Healthcare System, Los Angeles, California, United States
Contact: Principal Investigator (Matthew Rettig)VA Palo Alto Health Care System, Palo Alto, California, United States
Contact: Principal Investigator (Minal Vasanawala)Stanford University, Palo Alto, California, United States
Contact: Principal Investigator (Mallika Marar)UCSF, San Francisco, California, United States
Contact: Principal Investigator (Steven Seyedin)Rocky Mountain Cancer Centers, Denver, Colorado, United States
Contact: Principal Investigator (Allen Cohn)Cancer Specialists of North Florida, Jacksonville, Florida, United States
Contact: Principal Investigator (Richard Cassidy)Woodlands Medical Specialists, Pensacola, Florida, United States
Contact: Principal Investigator (Michael Poiesz)Piedmont Healthcare, Atlanta, Georgia, United States
Contact: Study coordinator (Sharon Joseph)Contact: Principal Investigator (Adam Nowlan)University of Chicago, Chicago, Illinois, United States
Contact: Principal Investigator (Mohammed Atiq)The Cancer Institute of Alexian Brothers, Elk Grove, Illinois, United States
Unity Point Clinic, Des Moines, Iowa, United States
Contact: Principal Investigator (Mark Kellerman)University of Kansas Hospital, Kansas City, Kansas, United States
Contact: Principal Investigator (Xinglei Shen)Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
Contact: Principal Investigator (Victor Lin)East Jefferson Hospital, Metairie, Louisiana, United States
Contact: Principal Investigator (Alton Oliver Sartor)University of Maryland Medical Ctr, Baltimore, Maryland, United States
Contact: Principal Investigator (Arif Hussain)Johns Hopkins Kimmel Com Cancer Ctr, Baltimore, Maryland, United States
Contact: Principal Investigator (Ana Kiess)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Mai Anh Huynh)Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
Contact: Principal Investigator (David J Einstein)BAMF Health, Grand Rapids, Michigan, United States
Contact: Principal Investigator (Brandon Mancini)Profound Research LLC, Royal Oak, Michigan, United States
William Beaumont Hospital, Royal Oak, Michigan, United States
Contact: Principal Investigator (Andrew Thompson)Mayo Clinic Rochester, Rochester, Minnesota, United States
Contact: Principal Investigator (Ryan Phillips)VA St Louis Health Care System, St Louis, Missouri, United States
Contact: Principal Investigator (Medhat Osman)Wash U School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Hiram Gay)The Urology Center PC DBA UroHealth Partners, Omaha, Nebraska, United States
Contact: Principal Investigator (Andrew Trainer)Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
Contact: Principal Investigator (Daniel Gorovets)Associated Med Professionals of NY, Syracuse, New York, United States
Contact: Principal Investigator (Steven Finkelstein)Montefiore Hospital, The Bronx, New York, United States
Contact: Principal Investigator (Benjamin A Gartrell)East Carolina University, Greenville, North Carolina, United States
Contact: Principal Investigator (Andrew Ju)Dayton Physicians, Kettering, Ohio, United States
Contact: Principal Investigator (Trevor Bluemel)Oregon Urology Institute, Springfield, Oregon, United States
Contact: Principal Investigator (Bryan Mehlhaff)Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Contact: Principal Investigator (Neal D Shore)Vanderbilt University Medical Center, Nashville, Tennessee, United States
Contact: Principal Investigator (Kerry Schaffer)Univ of Texas Southwest Med Center, Dallas, Texas, United States
Contact: Principal Investigator (Kevin Courtney)Rio Grande Urology, El Paso, Texas, United States
Contact: Principal Investigator (Jameson T Mendel)Virginia Oncology Associates, Norfolk, Virginia, United States
Contact: Principal Investigator (Mark Fleming)Blue Ridge Cancer Center, Wytheville, Virginia, United States
Contact: Principal Investigator (David Buck)Novartis Investigative Site, CABA, Buenos Aires, Argentina
Novartis Investigative Site, CABA, Argentina
Novartis Investigative Site, Caba, Argentina
Novartis Investigative Site, Darlinghurst, New South Wales, Australia
Novartis Investigative Site, Herston, Queensland, Australia
Novartis Investigative Site, Adelaide, South Australia, Australia
Novartis Investigative Site, Malvern, Victoria, Australia
Novartis Investigative Site, Linz, Austria
Novartis Investigative Site, Vienna, Austria
Novartis Investigative Site, Aalst, Belgium
Novartis Investigative Site, Ghent, Belgium
Novartis Investigative Site, Wilrijk, Belgium
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Calgary, Alberta, Canada
Novartis Investigative Site, Halifax, Nova Scotia, Canada
Novartis Investigative Site, London, Ontario, Canada
Novartis Investigative Site, Ottawa, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Québec, Quebec, Canada
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Guangzhou, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Bogota, Cundinamarca, Colombia
Novartis Investigative Site, Bogotá, Colombia
Novartis Investigative Site, Ostrava, Poruba, Czechia
Novartis Investigative Site, Olomouc, Czechia
Novartis Investigative Site, Prague, Czechia
Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France
Novartis Investigative Site, Angers, France
Novartis Investigative Site, Bordeaux, France
Novartis Investigative Site, Bron, France
Novartis Investigative Site, Clermont-Ferrand, France
Novartis Investigative Site, Rouen, France
Novartis Investigative Site, Saint-Herblain, France
Novartis Investigative Site, Munich, Bavaria, Germany
Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site, Aachen, Germany
Novartis Investigative Site, Augsburg, Germany
Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, Münster, Germany
Novartis Investigative Site, Rostock, Germany
Novartis Investigative Site, Athens, Greece
Novartis Investigative Site, Athens, Greece
Novartis Investigative Site, Thessaloniki, Greece
Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site, Budapest, Hungary
Novartis Investigative Site, Budapest, Hungary
Novartis Investigative Site, Beersheba, Israel
Novartis Investigative Site, Haifa, Israel
Novartis Investigative Site, Jerusalem, Israel
Novartis Investigative Site, Petah Tikva, Israel
Novartis Investigative Site, Tel Aviv, Israel
Novartis Investigative Site, Brescia, BS, Italy
Novartis Investigative Site, Cona, FE, Italy
Novartis Investigative Site, Genova, GE, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Pisa, PI, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Negrar, VR, Italy
Novartis Investigative Site, Milan, Italy
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Kobe, Hyōgo, Japan
Novartis Investigative Site, Yokohama, Kanagawa, Japan
Novartis Investigative Site, Chuo Ku, Tokyo, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Fukushima, Japan
Novartis Investigative Site, Ishikawa, Japan
Novartis Investigative Site, Kyoto, Japan
Novartis Investigative Site, Petaling Jaya, Selangor, Malaysia
Novartis Investigative Site, Kuala Lumpur, Malaysia
Novartis Investigative Site, Mexico City, Mexico City, Mexico
Novartis Investigative Site, Huxquilucan, Mexico
Novartis Investigative Site, Amsterdam, Netherlands
VA Caribbean Healthcare System, San Juan, Puerto Rico
Contact: Principal Investigator (Bartolo Santiago-Delgado)Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Bratislava, Slovakia
Novartis Investigative Site, Košice, Slovakia
Novartis Investigative Site, Nitra, Slovakia
Novartis Investigative Site, Trenčín, Slovakia
Novartis Investigative Site, Granada, Andalusia, Spain
Novartis Investigative Site, Barcelona, Catalonia, Spain
Novartis Investigative Site, El Palmar, Murcia, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Seville, Spain
Novartis Investigative Site, Valencia, Spain
Novartis Investigative Site, Geneva, Switzerland
Novartis Investigative Site, Lucerne, Switzerland
Novartis Investigative Site, Zurich, Switzerland
Novartis Investigative Site, Taipei, Taiwan
Novartis Investigative Site, Taipei, Taiwan
Novartis Investigative Site, Taipei, Taiwan
Novartis Investigative Site, Taoyuan, Taiwan
Novartis Investigative Site, Bristol, Avon, United Kingdom
Novartis Investigative Site, Guildford, Surrey, United Kingdom
Novartis Investigative Site, Sutton, Surrey, United Kingdom
Novartis Investigative Site, Coventry, United Kingdom
Novartis Investigative Site, London, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals